IMI launches AD research platform

The Innovative Medicines Initiative launched a joint Alzheimer's Disease Research Platform that the EU's public-private partnership said will facilitate collaboration and produce faster results from three IMI projects that have a combined budget of EUR 138 million ($145.3 million).

The IMI projects include AETIONOMY, which is developing a mechanism-based, rather than symptom-based, classification of neurodegenerative diseases including AD and Parkinson's disease with a budget of EUR 18 million ($19 million). The European Medical Information Framework (EMIF) is developing a platform for patient-level data to facilitate access to diverse data sources with EUR 56 million ($59 million). Lastly, the European Prevention of Alzheimer's Dementia (EPAD) is developing adaptive clinical trials of treatments designed to prevent the onset of dementia in early stage AD patients, with a budget of EUR 64 million ($67.4 million). ...